MRNA COVID-19 Vaccination During Pregnancy Not Linked to Autism or Developmental Disorders in Children, Major Study Confirms

Research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting has definitively concluded that receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with autism or other developmental disorders in children. These significant findings offer crucial new data regarding the long-term health outcomes for children whose mothers received vaccination around the time of conception or during gestation, providing substantial reassurance to expectant parents and healthcare providers worldwide.

Key Findings and Their Significance

The multi-center study, conducted by researchers within the esteemed Maternal-Fetal Medicine Units (MFMU) Network, meticulously evaluated 434 toddlers aged between 18 and 30 months. The comprehensive assessment found no discernible differences in neurodevelopmental outcomes between children born to mothers who received at least one dose of an mRNA COVID-19 vaccine during pregnancy or within 30 days prior to conception, and those born to unvaccinated mothers. This robust evidence directly addresses a prominent area of public concern and misinformation that has circulated since the advent of COVID-19 vaccines, particularly regarding their potential impact on fetal development and long-term child health.

In the United States, two primary types of COVID-19 vaccines are recommended: the messenger ribonucleic acid (mRNA) vaccine and a protein subunit vaccine. Both formulations have been consistently deemed safe and effective during all stages of pregnancy by leading health organizations such as the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the World Health Organization (WHO). These recommendations are rooted in the imperative to safeguard both maternal and infant health, given the heightened risks of severe COVID-19 illness in pregnant individuals and potential adverse pregnancy outcomes. The new data further solidifies the scientific consensus, adding a critical layer of long-term developmental reassurance.

Addressing Persistent Public Concerns: The Background to the Study

The COVID-19 pandemic ushered in an unprecedented era of public health challenges, including the rapid development and deployment of novel vaccine technologies. mRNA vaccines, while revolutionary in their efficacy and speed of development, were a new concept to many, leading to widespread questions and, unfortunately, a surge of misinformation. Concerns about vaccine safety, particularly for vulnerable populations like pregnant individuals and their unborn children, became a focal point of public discourse. Despite early and consistent assurances from scientific and medical bodies regarding the safety profile of mRNA vaccines—underscoring that mRNA does not alter human DNA and has a short half-life in the body—hesitancy persisted among some pregnant individuals.

This hesitancy was often fueled by a lack of long-term data, a gap the MFMU Network study aimed to fill. Prior research had largely focused on immediate maternal and neonatal outcomes, such as preterm birth, stillbirth, or congenital anomalies. While these studies consistently showed no adverse effects linked to vaccination, the question of neurodevelopmental disorders like autism, which manifest later in childhood, remained a significant point of anxiety for many prospective parents. The SMFM 2026 presentation directly tackles this critical, previously under-researched area, offering data that can profoundly influence vaccine confidence and uptake among pregnant populations globally.

Rigorous Methodology: A Closer Look at the Investigation

The investigation, conducted by researchers within the Maternal-Fetal Medicine Units Network, was meticulously designed as a prospective, multi-center, and observational study. It spanned from May 2024 to March 2025, ensuring a contemporary cohort reflective of current vaccine formulations and administration protocols. A total of 434 children were assessed, ranging in age from 18 to 30 months, a crucial developmental window for identifying early signs of autism spectrum disorder (ASD) and other developmental delays.

The study employed a carefully matched cohort design to enhance the accuracy and reliability of its comparisons. Half of the children (217) were born to mothers who had received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days immediately preceding conception. The control group comprised the remaining 217 children, born to mothers who did not receive an mRNA vaccine during the specified timeframe. To ensure the comparison was as accurate and unbiased as possible, vaccinated mothers were meticulously paired with unvaccinated mothers based on several critical demographic and obstetric factors. These matching criteria included the facility where they delivered (e.g., hospital, birth center), the exact date of delivery, insurance status, and race/ethnicity. This rigorous matching strategy aimed to minimize confounding variables that could otherwise influence developmental outcomes.

Certain pregnancies were deliberately excluded from both groups to maintain the study’s focus and integrity. These exclusions included pregnancies that concluded before 37 weeks of gestation (preterm births), those involving multiple babies (e.g., twins, triplets), or cases where the child was diagnosed with a major congenital malformation. By excluding these complex cases, the researchers ensured that the observed developmental outcomes could be more directly attributed to the vaccine exposure status rather than other significant medical or obstetric factors.

Comprehensive Developmental Assessments

When the children reached the age range of 1.5 to 2.5 years, a critical period for developmental screening, researchers employed a battery of standardized and widely validated assessment tools. The primary screening instrument utilized was the Ages and Stages Questionnaire, Version 3 (ASQ-3). The ASQ-3 is a parent-completed, norm-referenced screening tool that evaluates a child’s progress across five key developmental domains: communication, gross motor skills, fine motor skills, problem-solving abilities, and personal-social interaction. It is renowned for its accuracy in identifying children at risk for developmental delays.

To further corroborate and enrich the developmental data, the research team also reviewed results from several other established instruments. These included the Child Behavior Checklist (CBCL), which assesses a broad range of behavioral and emotional problems; the Modified Checklist for Autism in Toddlers, Revised, with Follow-up (M-CHAT-R/F), a highly sensitive screening tool specifically designed to identify children at risk for autism spectrum disorder; and the Early Childhood Behavior Questionnaire (ECBQ), which measures temperament dimensions in young children. The multi-faceted approach to developmental assessment ensured a holistic and robust evaluation of each child’s neurodevelopmental profile, leaving no stone unturned in the investigation of potential vaccine-related impacts.

Expert Commentary and Reaffirmation

The findings were met with significant positive reception from the medical community, with lead researchers emphasizing the reassuring nature of the results. Dr. George R. Saade, MD, a senior researcher on the study, and Professor and Chair of Obstetrics and Gynecology, as well as Associate Dean for Women’s Health, at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, articulated the core conclusion: "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine." His statement underscores the clear and unambiguous nature of the study’s findings, directly refuting claims of vaccine-induced developmental harm.

Adding to this sentiment, Dr. Brenna L. Hughes, MD, MSc, Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, highlighted the study’s methodological rigor and broader implications. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes remarked. Her emphasis on the "rigorous scientific process" and the involvement of an NIH clinical trials network lends significant weight to the study’s credibility, reinforcing its position as a definitive piece of research in the field. The MFMU Network, under the umbrella of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is renowned for its high standards in clinical research related to maternal and fetal health, further bolstering confidence in these results.

Broader Public Health Implications and Impact on Vaccine Confidence

These findings carry immense public health significance. The direct reassurance that mRNA COVID-19 vaccines do not cause autism or other developmental disorders is expected to play a crucial role in enhancing vaccine confidence among pregnant individuals and those planning pregnancy. Vaccine hesitancy, often fueled by legitimate concerns about unknown long-term effects on children, has been a persistent challenge in public health campaigns. This study directly addresses one of the most significant and emotionally charged fears, potentially leading to increased vaccination rates in a population particularly vulnerable to severe COVID-19 outcomes.

Higher vaccination rates among pregnant individuals translate into direct benefits: reduced risk of severe maternal illness, hospitalization, and even death; decreased risk of preterm birth and stillbirth associated with maternal COVID-19 infection; and passive antibody transfer to newborns, offering a degree of protection in their early, most vulnerable months. Public health bodies like the CDC and ACOG are likely to integrate these findings into their updated guidance and public communication strategies, further strengthening their recommendations for COVID-19 vaccination during pregnancy. Healthcare providers, particularly obstetricians, gynecologists, and pediatricians, will now have an even more robust evidence base to counsel their patients effectively, addressing anxieties with clear, data-driven information.

The Evolution of Vaccine Recommendations for Pregnant Individuals

The journey to confidently recommend COVID-19 vaccines during pregnancy has been an evolving one. Initially, out of an abundance of caution due to limited data specifically on pregnant populations during early clinical trials, initial guidance was more reserved. However, as real-world data from millions of vaccinated individuals, including a growing number of pregnant people, began to emerge, the safety profile became increasingly clear. Observational studies and registries quickly demonstrated that mRNA vaccines were not associated with increased risks of miscarriage, stillbirth, preterm birth, or congenital anomalies.

This consistent stream of positive data led major health organizations to progressively strengthen their recommendations, moving from "may be offered" to "strongly recommended" for all pregnant individuals. This shift reflected the accumulating evidence of vaccine safety combined with the undeniable risks of COVID-19 infection during pregnancy, which include a higher likelihood of intensive care unit admission, mechanical ventilation, and even death compared to non-pregnant women of reproductive age. The current study adds the final, crucial piece of the puzzle by addressing long-term neurodevelopment, thereby providing a comprehensive picture of safety across the entire spectrum of pregnancy and early childhood.

Understanding mRNA Vaccine Technology and Its Safety Profile

It is vital to reiterate the fundamental principles of mRNA vaccine technology to understand why concerns about DNA alteration or long-term developmental harm are scientifically unfounded. mRNA vaccines work by delivering a small, synthetic piece of messenger RNA into human cells. This mRNA carries instructions for the cells to produce a harmless piece of the SARS-CoV-2 spike protein. The body’s immune system recognizes this protein as foreign and builds antibodies and T-cells to fight it, thereby generating immunity.

Crucially, the mRNA never enters the nucleus of the cell, where human DNA is stored. It functions in the cytoplasm and is quickly degraded by the body’s natural processes, typically within a few days. It cannot alter a person’s genetic code, nor can it persist in the body to cause long-term, unforeseen effects on developing fetal cells. This biological mechanism, combined with the rigorous testing and now extensive real-world data, including the MFMU Network study, underpins the scientific community’s confidence in the safety of these vaccines for all populations, including pregnant individuals and their children.

Future Directions in Research

While this study provides robust reassurance regarding neurodevelopmental outcomes up to 30 months of age, the scientific community will continue to monitor the long-term health of children born to vaccinated mothers. Future research may extend the follow-up period to school age or beyond, exploring other potential health indicators or subtle developmental nuances. Additionally, studies may investigate the impact of booster doses during pregnancy or the effects of vaccination on other, less commonly studied child health parameters. However, the current findings significantly mitigate the most prominent and widespread concerns about neurodevelopment.

Funding, Transparency, and Peer Review

The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). This federal funding underscores the importance placed on understanding the effects of COVID-19 vaccination in pregnancy. The authors were careful to note that the conclusions presented are their own and do not necessarily reflect the official views of the National Institutes of Health, a standard disclaimer for federally funded research, maintaining scientific independence.

The findings were presented as Oral abstract #8, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," at the SMFM 2026 Pregnancy Meeting. The full, peer-reviewed manuscript is slated for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. This upcoming publication in a reputable journal ensures that the data has undergone rigorous scrutiny by independent experts, further validating its scientific merit and contributing to the global body of evidence supporting the safety of mRNA COVID-19 vaccination in pregnancy. This comprehensive study marks a significant milestone in pandemic-era research, providing definitive answers to critical questions about vaccine safety and child development.